CKD PROGRESSION IN PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G) IN A US MULTI-CENTER ASSESSMENT

https://storage.unitedwebnetwork.com/files/1099/2942635baf4ae3fb35c45333a9bb5c63.pdf
CKD PROGRESSION IN PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G) IN A US MULTI-CENTER ASSESSMENT
Briana
Ndife
Carolina Aldworth carolina.aldworth@novartis.com Novartis Pharmaceuticals Corporation Medical Affairs East Hanover
Kathleen P. Murphy kathleen_p.murphy@novartis.com Novartis Pharmaceuticals Corporation Medical Affairs East Hanover
Jennifer Nguyen jennifer-1.nguyen@novartis.com Novartis Pharmaceuticals Corporation Medical Affairs East Hanover
Irina Pivneva Irina.Pivneva@analysisgroup.com Analysis Group Health Economics and Outcomes Research Massachusetts
Marie Louise Edwards marielouise.edwards@analysisgroup.com Analysis Group Health Economics and Outcomes Research Massachusetts
Annika Anderson Annika.Anderson@analysisgroup.com Analysis Group Health Economics and Outcomes Research Massachusetts
James Signorovitch James.Signorovitch@analysisgroup.com Analysis Group Health Economics and Outcomes Research Massachusetts
Pietro Canetta pac2004@cumc.columbia.edu Columbia University Irving Medical Center Division of Nephrology, Department of Medicine New York